Sonoma Pharmaceuticals, Inc. (NasdaqCM: SNOA)
Health Care · Pharmaceuticals · US
$1.34
0.00% today · -72.3% 1Y
Sonoma Pharmaceuticals, Inc. (NasdaqCM: SNOA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $6.42M and employs 10 people.
Over the last twelve months the share price has lost 72.3%, trading between 0.85 and 5.36.
Tweenvest scores Sonoma Pharmaceuticals, Inc. across four factors: quality 41/100, value 75/100, growth 59/100. Its strongest factor is value.
SNOA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.42M
- Revenue (TTM)
- $21.92M
- P/E
- —
- EPS
- -1.01
- Dividend yield
- —
- Beta (5Y)
- 1.29
- 52-week high
- $5.36
- 52-week low
- $0.85
- Avg volume (3M)
- —
- Shares outstanding
- 4.79M
- Employees
- 10
- Next earnings
- —
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
- ISIN
- US83558L3033
- Founded
- 1999
- Listed since
- Jan 25, 2007
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.00 | -0.07% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.00 | -0.75% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.75 | +0.06% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.00 | +0.16% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.66 | +0.46% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.89 | -0.29% |
Figures last refreshed Aug 18, 2026.